PROGRAM CHAIRS
Ronan J. Kelly, MD
Director, Charles A. Sammons Cancer Center
Chief of Oncology
Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Endowed Chair of Immunology
Baylor University Medical Center
Dallas, Texas
Clinical Professor
Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland
Professor, Clinical Sciences Division at the
Translational Genomics Research Institute (TGEN)
Phoenix, Arizona
John Marshall, MD
Physician Executive Director
MedStar Health
Division Director
Integrated Hematology Oncology
Washington, DC
PROGRAM OVERVIEW
With the recent discovery of HER2-targeted therapy’s efficacy in patients with gastrointestinal cancers, the community oncology team is further challenged to keep abreast of the most recent data. That in concert with the new trial findings of patients with either GEJ or GC who respond to HER2-targeted antibody-drug conjugate therapy in spite of HER2-low levels of expression continue to challenge the community oncologist. The application of this new data can be supported through the understanding and use of practice guidelines which will be reviewed along with their supporting clinical trial findings. Finally, the knowledge to both recognize and treat adverse events associated with antibody-drug conjugates in the gastrointestinal cancer population is essential for the optimal care of these patients.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community medical oncologists, pathologists and others (e.g. nurse practitioner, pharmacist, physician assistant, oncology nurse) involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize relevance of HER2 expression in GEJ and advanced gastric cancer management, including best practices for assessment.
- Evaluate current clinical trial findings informing available and emerging treatment strategies in gastric and GEJ cancer management.
- Recognize appropriate strategies for monitoring and management of potential toxicities associated with HER2-targeted antibody-drug conjugate therapies, including interstitial lung disease.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
| Faculty Member | Disclosures |
| Ronan J. Kelly, MD | Advisory board member/Consultant for Daiichi Sankyo, AstraZeneca, Astellas Pharma, Eli Lilly, Bristol Myers Squibb, Beigen, EMD Serono, Grail, Exact Sciences, Novartis, Novocure, Toray, Takeda and Merck |
| John Marshall, MD | Consultant for AstraZeneca, Merck, Bayer, Taiho, Seagen, Pfizer, Takeda, Astellas, Caris, Arcus, Indivumed; Speakers Bureau for AstraZeneca, Merck, Bayer, Taiho, Seagen, Pfizer, Takeda, Astellas, Caris. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Shannon Mutch MS, RN, OCN, has nothing to disclose.
- M. Susan Burke, MD, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Anita Misra-Press, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.
- Dan Dasilva, Accreditation & Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: June 19, 2024
EXPIRATION DATE: June 19, 2025
Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
